bluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
bluebird bio (BLUE) Posts Wider-than-Expected Q3 Loss
November 5, 2015 6:45 AM ESTbluebird bio (NASDAQ: BLUE) reported Q3 EPS of ($1.18), $0.24 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $1.32 million versus the consensus estimate of $5.2 million.
Cash, cash equivalents and marketable securities as of September 30, 2015 were $901.7 million, compared to $492.0 million as of... More
bluebird bio (BLUE) Bullish View Reiterate at Post Q3 and Ahead of ASH Abstract Data -Oppenheimer
November 5, 2015 6:38 AM ESTOppenheimer analyst Wendy Lam reiterated an Outperform rating and $162 price target on bluebird bio (NASDAQ: BLUE) following Q3 results.
Lam commented, "BLUE reported 3Q15 loss per share of ($1.18) and ended the quarter with $901.7M in cash, cash equivalents, and marketable securities; we have updated our... More
